Neisserial Heparin Binding Antigen (NHBA) Contributes to the Adhesion of Neisseria meningitidis to Human Epithelial Cells
Open Access
- 25 October 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (10), e0162878
- https://doi.org/10.1371/journal.pone.0162878
Abstract
Neisserial Heparin Binding Antigen (NHBA) is a surface-exposed lipoprotein ubiquitously expressed by Neisseria meningitidis strains and an antigen of the Bexsero® vaccine. NHBA binds heparin through a conserved Arg-rich region that is the target of two proteases, the meningococcal NalP and human lactoferrin (hLf). In this work, in vitro studies showed that recombinant NHBA protein was able to bind epithelial cells and mutations of the Arg-rich tract abrogated this binding. All N-terminal and C-terminal fragments generated by NalP or hLf cleavage, regardless of the presence or absence of the Arg-rich region, did not bind to cells, indicating that a correct positioning of the Arg-rich region within the full length protein is crucial. Moreover, binding was abolished when cells were treated with heparinase III, suggesting that this interaction is mediated by heparan sulfate proteoglycans (HSPGs). N. meningitidis nhba knockout strains showed a significant reduction in adhesion to epithelial cells with respect to isogenic wild-type strains and adhesion of the wild-type strain was inhibited by anti-NHBA antibodies in a dose-dependent manner. Overall, the results demonstrate that NHBA contributes to meningococcal adhesion to epithelial cells through binding to HSPGs and suggest a possible role of anti-Bexsero® antibodies in the prevention of colonization.Keywords
Funding Information
- Università di Bologna
- Università di Bologna
- University of Siena
- Australian National Health and Medical Research Council (ProjProject Grant 1099278 and Career Development Fellowship 1045235)
- Australian National Health and Medical Research Council (Program Grant 1071659)
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
- GSK Vaccines S.r.l.
This publication has 34 references indexed in Scilit:
- Conservation of Meningococcal Antigens in the Genus NeisseriamBio, 2013
- The Adhesin Complex Protein (ACP) of Neisseria meningitidis Is a New Adhesin with Vaccine PotentialmBio, 2013
- The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigensVaccine, 2012
- Two Strikingly Different Signaling Pathways Are Induced by Meningococcal Type IV Pili on Endothelial and Epithelial CellsInfection and Immunity, 2012
- Structure of the C-terminal Domain of Neisseria Heparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine against Neisseria meningitidisJournal of Biological Chemistry, 2011
- Transcellular Passage of Neisseria meningitidis across a Polarized Respiratory EpitheliumInfection and Immunity, 2010
- Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humansProceedings of the National Academy of Sciences of the United States of America, 2010
- Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidisVaccine, 2009
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences of the United States of America, 2006
- Characterization of MspA, an Immunogenic Autotransporter Protein That Mediates Adhesion to Epithelial and Endothelial Cells in Neisseria meningitidisInfection and Immunity, 2006